Fatima Ashfaq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fatima Ashfaq has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Allahdad Khan
Department of Medicine, Nishtar Medical University, Multan, Pakistan
2 shared publications - Raheel Ahmed
Newcastle Hospitals NHS Foundation Trust, United Kingdom; Translational and Clinical Research Institute, Newcastle University, United Kingdom
2 shared publications Ahmad Zain
Department of Medicine Services Institute of Medical Sciences Lahore Pakistan
1 shared publication- Ahmad Zain
Department of Internal Medicine, UCHealth Parkview Medical Center, Pueblo, CO
1 shared publication - Alina Sehar
Internal Medicine, United Medical and Dental College, Karachi, PAK
1 shared publication Aqsa Komel
Department of Medicine, Nishtar Medical University, Multan, Pakistan
1 shared publication
Latest Publications
- Open Access
- 29 September 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 10 (1) , 211-219
Trends in mortality from acute myocardial infarction among the obese population in the United States from 1999 to 2020: insights from CDC WONDER
Introduction: Acute myocardial infarction (AMI) remains a leading cause of death globally, with obesity identified as a significant risk factor for increased incidence and poorer post-event outcomes. Understanding trends in AMI mortality among obese populations is crucial for informing public health strategies, especially in light of rising obesity rates.Material and methods: This retrospective study analyzed data from the CDC WONDER database to examine AMI-related mortality among obese individuals (ICD-10 codes I21 for AMI and E66 for obesity) from 1999 to 2020. Mortality rates were assessed using crude mortality rates (CMR) and age-adjusted mortality rates (AAMR) per 100,000, stratified by year, gender, race/ethnicity, state, and urban-rural status. Average annual percent change (AAPC) was calculated to identify trends over the study period.Results: From 1999 to 2020, there were 39,793 obesity-related AMI deaths. The AAPC for the entire period was 1.75 (95% CI: 1.06 to 2.45, p < 0.001). For men, the AAPC was 2.81, while for women, it was 1.12. Notably, African American individuals saw a significant increase in AMI mortality from 2018 to 2020 (AAPC = 19.28). Geographically, the Midwest, South, and West regions experienced upward trends, while the Northeast saw a slight decline. Smaller metropolitan and non-metropolitan areas showed consistent increases.Conclusions: The study highlights an upward trend in AMI-related mortality among the obese population in the U.S. from 1999 to 2020. Targeted public health interventions are needed to address these trends, particularly in high-risk populations.
- 29 September 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 10 (1) , 211-219
Open AccessTrends in mortality from acute myocardial infarction among the obese population in the United States from 1999 to 2020: insights from CDC WONDER
Introduction: Acute myocardial infarction (AMI) remains a leading cause of death globally, with obesity identified as a significant risk factor for increased incidence and poorer post-event outcomes. Understanding trends in AMI mortality among obese populations is crucial for informing public health strategies, especially in light of rising obesity rates.Material and methods: This retrospective study analyzed data from the CDC WONDER database to examine AMI-related mortality among obese individuals (ICD-10 codes I21 for AMI and E66 for obesity) from 1999 to 2020. Mortality rates were assessed using crude mortality rates (CMR) and age-adjusted mortality rates (AAMR) per 100,000, stratified by year, gender, race/ethnicity, state, and urban-rural status. Average annual percent change (AAPC) was calculated to identify trends over the study period.Results: From 1999 to 2020, there were 39,793 obesity-related AMI deaths. The AAPC for the entire period was 1.75 (95% CI: 1.06 to 2.45, p < 0.001). For men, the AAPC was 2.81, while for women, it was 1.12. Notably, African American individuals saw a significant increase in AMI mortality from 2018 to 2020 (AAPC = 19.28). Geographically, the Midwest, South, and West regions experienced upward trends, while the Northeast saw a slight decline. Smaller metropolitan and non-metropolitan areas showed consistent increases.Conclusions: The study highlights an upward trend in AMI-related mortality among the obese population in the U.S. from 1999 to 2020. Targeted public health interventions are needed to address these trends, particularly in high-risk populations.
- Open Access
- 21 June 2025
- Published by Elsevier in International Journal of Cardiology Congenital Heart Disease
- Vol. 21, 100602
Trends in mortality from pulmonary hypertension amongst population with congenital heart disease in the United States from 1999 to 2020: A CDC WONDER analysis
- 21 June 2025
- Published by Elsevier in International Journal of Cardiology Congenital Heart Disease
- Vol. 21, 100602
Open AccessTrends in mortality from pulmonary hypertension amongst population with congenital heart disease in the United States from 1999 to 2020: A CDC WONDER analysis
- Open Access
- 7 September 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (9) , e1550
Lahore's encounter with Naegleria fowleri: Unveiling health hazards and heightened concerns
- 7 September 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (9) , e1550
Open AccessLahore's encounter with Naegleria fowleri: Unveiling health hazards and heightened concerns
- Open Access
- 25 November 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (47) , e31455
Rare finding of duodenal lymphangioma in a patient with Helicobacter pylori associated gastritis: A case report
Rationale: Lymphangiomas are lymphatic malformations most commonly found in the head, neck and axilla. Their incidence in gastrointestinal tract, especially duodenum is very rare. They are mostly congenital and are usually seen in children. Owing to their asymptomatic nature, these tumors are often diagnosed incidentally. Surgical resection is the definite treatment. Patient concerns: We represent a case of a 30-year-old male with duodenal lymphangioma with presentation of intermittent dyspepsia for 1 year, partially relieved by a proton pump inhibitor. Diagnoses: Upon physical examination, there was mild tenderness observed in the epigastrium. The rest of the physical examination was unremarkable. His complete blood count report was unremarkable. Upon a negative stool for Helicobacter pylori antigen test, the patient underwent an esophagogastroduodenoscopy which revealed H pylori gastritis and a duodenal lymphangioma. Interventions: Patient was put on triple therapy (clarithromycin, amoxicillin and omeprazole) for 14 days and his symptoms improved. The lymphangioma was not resected owing to small size. Outcomes: Patient was followed till 1 year and his symptoms had improved. Lessons: The case describes a correlation between H pylori gastritis and a duodenal lymphangioma. There is likely to be an association between the two and therefore, further studies are required to find out any relationship that may exist between the 2 conditions.
- 25 November 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (47) , e31455
Open AccessRare finding of duodenal lymphangioma in a patient with Helicobacter pylori associated gastritis: A case report
Rationale: Lymphangiomas are lymphatic malformations most commonly found in the head, neck and axilla. Their incidence in gastrointestinal tract, especially duodenum is very rare. They are mostly congenital and are usually seen in children. Owing to their asymptomatic nature, these tumors are often diagnosed incidentally. Surgical resection is the definite treatment. Patient concerns: We represent a case of a 30-year-old male with duodenal lymphangioma with presentation of intermittent dyspepsia for 1 year, partially relieved by a proton pump inhibitor. Diagnoses: Upon physical examination, there was mild tenderness observed in the epigastrium. The rest of the physical examination was unremarkable. His complete blood count report was unremarkable. Upon a negative stool for Helicobacter pylori antigen test, the patient underwent an esophagogastroduodenoscopy which revealed H pylori gastritis and a duodenal lymphangioma. Interventions: Patient was put on triple therapy (clarithromycin, amoxicillin and omeprazole) for 14 days and his symptoms improved. The lymphangioma was not resected owing to small size. Outcomes: Patient was followed till 1 year and his symptoms had improved. Lessons: The case describes a correlation between H pylori gastritis and a duodenal lymphangioma. There is likely to be an association between the two and therefore, further studies are required to find out any relationship that may exist between the 2 conditions.
- Open Access
- 9 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26680
Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis
Coronary vessel disease (CVD) is a class of diseases that impacts the blood vessels and heart and is one of the leading causes of disability and death. CVD includes cerebrovascular disease and coronary heart disease, both illnesses of the vessels transporting the oxygenated blood to the brain or heart. Colchicine is an inexpensive and old drug with strong anti-inflammatory effects. Numerous randomized control trials (RCTs) have demonstrated the effectiveness of low-dose colchicine for the prevention of severe cardiovascular events without showing any signs of serious adverse effects within the regime of treatment. In the current meta-analysis, we aim to assess the efficacy and safety of colchicine for secondary cardiovascular outcome prevention among patients with clinically proven CVD. The current meta-analysis was carried out using the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. PUBMED, Cochrane, and EMBASE databases were used to search for RCTs comparing colchicine and placebos for the prevention of secondary cardiovascular outcomes. The primary efficacy endpoint was mortality due to cardiovascular disease, stroke, urgent coronary revascularization, and myocardial infarction. Secondary efficacy outcomes included death due to all-cause mortality. Seven RCTs were reviewed, with a pooled sample size of 12114, out of which 6099 were randomized to the colchicine group, and 6015 were randomized to the control group. The decrease in cardiovascular events, including myocardial infarction, stroke, urgent coronary revascularization, and cardiac-related death, was significantly lower in patients randomized to colchicine (p-value0.05). In patients with CVD, compared to standard medical therapy, colchicine significantly decreases the risk of cardiovascular events such as cardiovascular-related death, myocardial infarction, stroke, and urgent coronary revascularizations.
- 9 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26680
Open AccessEfficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis
Coronary vessel disease (CVD) is a class of diseases that impacts the blood vessels and heart and is one of the leading causes of disability and death. CVD includes cerebrovascular disease and coronary heart disease, both illnesses of the vessels transporting the oxygenated blood to the brain or heart. Colchicine is an inexpensive and old drug with strong anti-inflammatory effects. Numerous randomized control trials (RCTs) have demonstrated the effectiveness of low-dose colchicine for the prevention of severe cardiovascular events without showing any signs of serious adverse effects within the regime of treatment. In the current meta-analysis, we aim to assess the efficacy and safety of colchicine for secondary cardiovascular outcome prevention among patients with clinically proven CVD. The current meta-analysis was carried out using the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. PUBMED, Cochrane, and EMBASE databases were used to search for RCTs comparing colchicine and placebos for the prevention of secondary cardiovascular outcomes. The primary efficacy endpoint was mortality due to cardiovascular disease, stroke, urgent coronary revascularization, and myocardial infarction. Secondary efficacy outcomes included death due to all-cause mortality. Seven RCTs were reviewed, with a pooled sample size of 12114, out of which 6099 were randomized to the colchicine group, and 6015 were randomized to the control group. The decrease in cardiovascular events, including myocardial infarction, stroke, urgent coronary revascularization, and cardiac-related death, was significantly lower in patients randomized to colchicine (p-value0.05). In patients with CVD, compared to standard medical therapy, colchicine significantly decreases the risk of cardiovascular events such as cardiovascular-related death, myocardial infarction, stroke, and urgent coronary revascularizations.